Kyntra Bio, Inc. KYNB
Set alert
4.57 USD -0.08 -1.72%
At close · Oct 30
4.85 +0.28 +6.13%
After hours · Oct 30, 4:05 PM ET
4.48 Day range 4.70
4.50 52-week range 11.12
- YTD
- -47.95%
- 1 year
- -58.61%
- Open
- 4.52
- Prev close
- 4.65
- Mkt cap
- 18.50M
- Vol
- 24.42K
- Avg vol
- 21.37K
- EPS
- -7.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.48
- High
- 4.70
3M chart
Signals (16)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
Financials — quick view
KYNB Revenue — quarterly -1.47M
KYNB Net income — quarterly 11.97M
KYNB EPS — quarterly 2.96
News
- Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
- Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
- Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
- Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
- Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
- Kyntra Bio To Reduce The Maximum Aggregate Payments Under Its Royalty Financing Agreement From $125M To $65M; Co. Accelerated Payment Of $42.6M Upfront, Bringing Total Payments Made To Date To $50M; Remaining Payments, Capped At $15M, To Be Paid From 50% Of The Revenue Received From Astellas In The Astellas Territories Excluding Japan
- Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
- Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
- Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates
Your note
Sign in to keep a note on KYNB — it syncs with the Stock Master app.